{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:31:52Z","timestamp":1788870712253,"version":"build-2803163510"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Due to the impact of high-potency synthetic opioids on medication for opioid use disorder (MOUD) initiation, hospital-based addiction clinicians adapted their practice to improve care, with decisions often guided by limited evidence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To derive expert consensus on best practices for hospital-initiated MOUD among patients with OUD using high-potency synthetic opioids.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This survey study used a 2-round Delphi process conducted from January to April 2025. National experts were hospital-based physicians or advanced practice clinicians who treated at least 100 hospitalized patients with OUD in the last 2 years and self-identified as an expert in methadone and buprenorphine initiation. Experts were purposively sampled based on practice location and addiction board certification. Data were analyzed from April 2025 to March 2026.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was consensus on the appropriateness of specific practices. Appropriateness was evaluated using a 9-point Likert scale from 1, indicating very inappropriate to 9, very appropriate. The presence of consensus was determined using the RAND\/UCLA appropriateness method; if consensus was obtained, it was stratified into inappropriate (median 1-3), uncertain (median 4-6), or appropriate (median 7-9).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 48 experts, 42 (87.5%; median [IQR] age, 41 [36.0-45.8] years; 25 [59.5%] female) completed round 1 and 41 of these (97.6%) completed round 2. Most were physicians (36 participants [85.7%]); of those, 30 (83.3%) were board certified in addiction medicine, 3 (14.3%) in addiction psychiatry, 2 (5.6%) in both, and 1 (2.4%) in neither. Experts treated a median (IQR) of 200 (100-315) hospitalized patients with OUD in the past year. There was consensus that buprenorphine and methadone initiation were appropriate, while the appropriateness of naltrexone initiation was uncertain. Consensus was reached that rapid methadone initiation was appropriate. Regarding buprenorphine initiation practices, experts reached consensus that high- and low-dose initiation were appropriate, traditional initiation was of uncertain appropriateness, and rescue was inappropriate. There was consensus that provision of non-MOUD full agonist opioids was appropriate to treat opioid withdrawal during methadone initiation, as a bridge during buprenorphine initiation, and to treat withdrawal among patients declining MOUD.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this survey study of hospital-based addiction specialty clinicians, consensus was reached on hospital-initiated MOUD and treatment of opioid withdrawal. These best practices can inform current clinical approaches and reflect the need for more robust research to evaluate effectiveness and safety.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.11514","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:30:24Z","timestamp":1778167824000},"page":"e2611514","source":"Crossref","is-referenced-by-count":2,"title":["Best Practices for Hospital-Based Initiation of Medications for Opioid Use Disorder"],"prefix":"10.1001","volume":"9","author":[{"given":"Shawn M.","family":"Cohen","sequence":"first","affiliation":[{"name":"Program in Addiction Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Straus","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Pomeranz","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette M.","family":"Tetrault","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa B.","family":"Weimer","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Joudrey","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"6","key":"zcs260005r2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamainternmed.2023.7282","article-title":"Caring for hospitalized adults with opioid use disorder in the era of fentanyl: a review.","volume":"184","author":"Englander","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zcs260005r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26077","article-title":"Hospital-based methadone and buprenorphine initiation practices by addiction consult services.","volume":"8","author":"Cohen","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zcs260005r4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","article-title":"Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl.","volume":"17","author":"Bird","year":"2023","journal-title":"J Addict Med"},{"key":"zcs260005r5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment.","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"zcs260005r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"1","key":"zcs260005r8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12954-023-00893-9","article-title":"\u201cAs safe as possible\u201d: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids.","volume":"20","author":"Frank","year":"2023","journal-title":"Harm Reduct J"},{"issue":"4","key":"zcs260005r9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/ADM.0000000000001324","article-title":"Piloting a hospital-based rapid methadone initiation protocol for fentanyl.","volume":"18","author":"Liu","year":"2024","journal-title":"J Addict Med"},{"key":"zcs260005r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209004","article-title":"Safety of rapid inpatient methadone initiation protocol: a retrospective cohort study.","volume":"148","author":"Racha","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"3","key":"zcs260005r11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/08897077231185655","article-title":"Rapid methadone induction in a general hospital setting: a retrospective, observational analysis.","volume":"44","author":"Casey","year":"2023","journal-title":"Subst Abus"},{"issue":"5","key":"zcs260005r12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/ADM.0000000000001362","article-title":"Induction to methadone 80 mg in the first week of treatment of patients who use fentanyl: a case series from an outpatient opioid treatment program.","volume":"18","author":"Steiger","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"zcs260005r13","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"4","key":"zcs260005r14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"9","key":"zcs260005r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl.","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zcs260005r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zcs260005r17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","article-title":"High-dose buprenorphine initiation: a scoping review.","volume":"18","author":"Wong","year":"2024","journal-title":"J Addict Med"},{"issue":"8","key":"zcs260005r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.28119","article-title":"High-dose buprenorphine treatment in the setting of fentanyl.","volume":"8","author":"Tsui","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zcs260005r19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zcs260005r20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"7","key":"zcs260005r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder.","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zcs260005r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1572","article-title":"High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids.","volume":"6","author":"Snyder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zcs260005r23","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/ADM.0000000000001133","article-title":"Rapid low-dose buprenorphine initiation for hospitalized patients with opioid use disorder.","volume":"17","author":"Sokolski","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"zcs260005r24","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis.","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"1","key":"zcs260005r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (Accurate Consensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi.","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"key":"zcs260005r27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.techfore.2019.07.002","article-title":"Improving the practical application of the Delphi method in group-based judgment: a six-step prescription for a well-founded and defensible process.","volume":"147","author":"Belton","year":"2019","journal-title":"Technol Forecast Soc Change"},{"issue":"4","key":"zcs260005r28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness.","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"9","key":"zcs260005r29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/jhm.12893","article-title":"Management of opioid use disorder and associated conditions among hospitalized adults: a consensus statement from the Society of Hospital Medicine.","volume":"17","author":"Calcaterra","year":"2022","journal-title":"J Hosp Med"},{"issue":"12","key":"zcs260005r30","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021.","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"key":"zcs260005r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis.","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zcs260005r32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ADM.0000000000001163","article-title":"Survey of buprenorphine low-dose regimens used by healthcare institutions.","volume":"17","author":"Hardy","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"zcs260005r33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"1","key":"zcs260005r34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.sleh.2014.12.010","article-title":"National Sleep Foundation\u2019s sleep time duration recommendations: methodology and results summary.","volume":"1","author":"Hirshkowitz","year":"2015","journal-title":"Sleep Health"},{"issue":"1","key":"zcs260005r35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s13054-023-04718-w","article-title":"An international RAND\/UCLA expert panel to determine the optimal diagnosis and management of burn inhalation injury.","volume":"27","author":"Milton-Jones","year":"2023","journal-title":"Crit Care"},{"issue":"5","key":"zcs260005r36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001431","article-title":"Validation of prescribing appropriateness criteria for older Australians using the RAND\/UCLA appropriateness method.","volume":"2","author":"Basger","year":"2012","journal-title":"BMJ Open"},{"issue":"12","key":"zcs260005r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.39968","article-title":"Expert panel consensus on management of advanced cancer-related pain in individuals with opioid use disorder.","volume":"4","author":"Merlin","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zcs260005r38","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamaoncol.2022.2191","article-title":"Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder.","volume":"8","author":"Fitzgerald Jones","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"zcs260005r39","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1002\/cncr.34921","article-title":"Expert consensus-based guidance on approaches to opioid management in individuals with advanced cancer-related pain and nonmedical stimulant use.","volume":"129","author":"Jones","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"zcs260005r41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ADM.0000000000000935","article-title":"Rapid transition to buprenorphine in a patient with methadone-related QTc interval prolongation.","volume":"16","author":"Brogdon","year":"2022","journal-title":"J Addict Med"},{"issue":"2","key":"zcs260005r42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ADM.0000000000001073","article-title":"Enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation.","volume":"17","author":"Randall","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"zcs260005r43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13722-023-00368-z","article-title":"Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.","volume":"18","author":"Thakrar","year":"2023","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"zcs260005r44","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1097\/ADM.0000000000001007","article-title":"Buprenorphine initiation in the era of high-potency synthetic opioids: a call for community-based participatory research to help learning health systems provide precision medicine for opioid use disorder.","volume":"16","author":"Fiellin","year":"2022","journal-title":"J Addict Med"},{"issue":"23","key":"zcs260005r45","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1001\/jama.2023.21288","article-title":"Trends in before medically advised discharges for patients with opioid use disorder, 2016-2020.","volume":"330","author":"Thakrar","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"zcs260005r46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jnma.2020.03.014","article-title":"The importance of diversity and inclusion in the healthcare workforce.","volume":"112","author":"Stanford","year":"2020","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"zcs260005r47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1353\/hpu.2018.0036","article-title":"The racial and ethnic composition and distribution of primary care physicians.","volume":"29","author":"Xierali","year":"2018","journal-title":"J Health Care Poor Underserved"},{"issue":"4","key":"zcs260005r48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.amepre.2024.12.020","article-title":"Widening racial disparities in the U.S. overdose epidemic.","volume":"68","author":"Smith","year":"2025","journal-title":"Am J Prev Med"},{"issue":"5","key":"zcs260005r49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1176\/appi.ajp.20230917","article-title":"Understanding and addressing widening racial inequalities in drug overdose.","volume":"181","author":"Friedman","year":"2024","journal-title":"Am J Psychiatry"},{"key":"zcs260005r50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jclinepi.2018.03.007","article-title":"Lack of preregistered analysis plans allows unacceptable data mining for and selective reporting of consensus in Delphi studies.","volume":"99","author":"Grant","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zcs260005r51","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/acem.14782","article-title":"Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorder.","volume":"30","author":"D\u2019Onofrio","year":"2023","journal-title":"Acad Emerg Med"},{"issue":"8","key":"zcs260005r52","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27016","article-title":"Injectable-only overlapping buprenorphine starting protocol in a low-threshold setting.","volume":"8","author":"Waters","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zcs260005r53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/ADM.0000000000000955","article-title":"Management of xylazine withdrawal in a hospitalized patient: a case report.","volume":"16","author":"Ehrman-Dupre","year":"2022","journal-title":"J Addict Med"},{"issue":"15","key":"zcs260005r54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.15585\/mmwr.mm7415a2","article-title":"Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients\u2014Philadelphia, Pennsylvania, September 2024-January 2025.","volume":"74","author":"Huo","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zcs260005r1","doi-asserted-by":"crossref","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"Leshner","year":"2019"},{"key":"zcs260005r26","volume-title":"RAND Methodological Guidance for Conducting and Critically Appraising Delphi Panels","author":"Khodyakov","year":"2023"},{"key":"zcs260005r40","volume-title":"The RAND\/UCLA Appropriateness Method User\u2019s Manual","author":"Fitch","year":"2001"},{"key":"zcs260005r6","unstructured":"Substance Abuse and Mental Health Services Administration. Tip 63: medications for opioid use disorder. Published July 2021. Accessed January 5, 2026. https:\/\/library.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848762\/cohen_2026_cs_260005_1777584088.09966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:30:28Z","timestamp":1778167828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848762"}},"subtitle":["A Consensus Statement"],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11514","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}